2024

dbb-wp
10 months

Duopharma Biotech and Universiti Kebangsaan Malaysia Partner to Elevate Halal Standards in Healthcare

MoUs with Centre for Affordable Diagnostics & Therapeutics Limited and PAMOJA Therapeutics BV seek to repurpose anti-malarial drug artesunate for cancer therapy and other applications

dbb-wp
10 months

Duopharma Biotech records strong growth in Q3 FY2024

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
1 year

Duopharma Biotech Records Robust Financial Performance in Q2 2024

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
1 year

Duopharma Biotech Returns to Support Balanced Nutrition and Promote Healthy Breakfasts Among Schoolchildren

Duopharma Biotech Berhad is supporting efforts to promote better nutrition among schoolchildren for the second year running. Through the CHAMPS® Nutribar range, the Company’s leading nutrition brand CHAMPS® is the main sponsor of the nationwide Kempen Pemakanan Seimbang CHAMPS® targeted at primary school students.

dbb-wp
1 year

Duopharma Biotech Pursues Collaboration Opportunities in Qatar Outreach

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
1 year

Duopharma Biotech Pursues Growth Strategy Focusing on New Markets and Innovative Offerings

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
1 year

Duopharma Biotech brings Flavettes Glow to Indonesia

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
1 year

Duopharma Biotech optimistic on 2024 outlook with Q1FY2024 results

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
1 year

Duopharma Biotech forms R&D partnerships for new therapies

MoUs with Centre for Affordable Diagnostics & Therapeutics Limited and PAMOJA Therapeutics BV seek to repurpose anti-malarial drug artesunate for cancer therapy and other applications

dbb-wp
2 years

Duopharma Biotech partners Owen Mumford to distribute medical devices

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.